Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Authors

Nancy L. Bartlett, Washington University School of Medicine in St. Louis
Robert Chen, City of Hope
Michelle A. Fanale, University of Texas Health Science Center at Houston
Pauline Brice, Hospital Saint-Louis
Ajay Gopal, University of Washington - Seattle Campus
Scott E. Smith, Loyola University Chicago
Ranjana Advani, Stanford University
Jeffrey V. Matous, Colorado Blood Cancer Institute
Radhakrishnan Ramchandren, Karmanos Cancer Institute
Joseph D. Rosenblatt, University of Miami
Dirk Huebner, Takeda Pharmaceuticals International Company
Pamela Levine, Seattle Genetics, Inc.
Laurie Grove, Seattle Genetics, Inc.
Andres Forero-Torres, University of Alabama - BirminghamFollow

Journal

Journal of Hematology & Oncology

Publication Date

2014

Volume

7

Inclusive Pages

24

Document Type

Open Access Publication

Rights and Permissions

Bartlett et al. Journal of Hematology & Oncology 2014, 7:24 http://www.jhoonline.org/content/7/1/24

Recommended Citation

Bartlett, Nancy L.; Chen, Robert; Fanale, Michelle A.; Brice, Pauline; Gopal, Ajay; Smith, Scott E.; Advani, Ranjana; Matous, Jeffrey V.; Ramchandren, Radhakrishnan; Rosenblatt, Joseph D.; Huebner, Dirk; Levine, Pamela; Grove, Laurie; and Forero-Torres, Andres, "Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies." Journal of Hematology & Oncology. 7, 24. (2014).
https://digitalcommons.wustl.edu/open_access_pubs/2571